NCT01844180

A Phase 2, Multi-center Study to Evaluate the Efficacy and Safety of ONO-2952 in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

A Phase 2, Multi-center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ONO-2952 in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 200 (actual)
• Sponsor: Ono Pharma USA Inc · Industry
• Sex: Female
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The objective of this study is to explore efficacy, safety and tolerability of ONO-2952 in female subjects with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D).

Conditions

• Irritable Bowel Syndrome (IBS)

Interventions

Type	Name	Description
DRUG	ONO-2952
DRUG	ONO-2952 Matching Placebo

Timeline

• Start date: 2013-04-01
• Primary completion: 2014-07-01
• First posted: 2013-05-01
• Last updated: 2016-04-15

Locations

48 sites across 1 country: United States